However, the trade-off observed for IPF and COPD [17] can also be observed herein, since in the post-COVID-19 group, the highest pulmonary test scores were found for the patients with the GG genotype, suggesting differential activity of desmoplakins according to the timely disease process (acute or chronic) and the patient’s physiological status (i.e., age, comorbidities, and inflammatory status). The gene discussed is DSP; the disease is COVID-19.